- By insider
Myriad Genetics Inc (MYGN) files its latest 10-K with SEC for the fiscal year ended on June 30, 2017. Myriad Genetics Inc is a molecular diagnostic company. It develops and markets novel predictive medicine, personalized medicine and prognostic medicine tests. It also provides physicians with information to solve unmet medical needs. Myriad Genetics Inc has a market cap of $1.91 billion; its shares were traded at around $27.98 with a P/E ratio of 62.21 and P/S ratio of 2.61. Myriad Genetics Inc had annual average EBITDA growth of 6.20% over the past five years.
For the last quarter Myriad Genetics Inc reported a revenue of $200.5 million, compared with the revenue of $186.4 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $771.4 million, an increase of 2.3% from last year. For the last five years Myriad Genetics Inc had an average revenue growth rate of 8.2% a year.
The reported diluted earnings per share was 32 cents for the year, a decline of 81.3% from the previous year. Over the last five years Myriad Genetics Inc had an average EPS decline of 20.1% a year. The Myriad Genetics Inc had an operating margin of 6.4%, compared with the operating margin of 22.13% a year before. The 10-year historical median operating margin of Myriad Genetics Inc is 35.81%. The profitability rank of the company is 8 (out of 10).
At the end of the fiscal year, Myriad Genetics Inc has the cash and cash equivalents of $102.4 million, compared with $68.5 million in the previous year. The long term debt was $99.1 million. The interest coverage to the debt is 8.2. Myriad Genetics Inc has a financial strength rank of 7 (out of 10).
At the current stock price of $27.98, Myriad Genetics Inc is traded at 41.3% discount to its historical median P/S valuation band of $47.67. The P/S ratio of the stock is 2.61, while the historical median P/S ratio is 4.39. The stock lost 5.02% during the past 12 months.
For the complete 20-year historical financial data of MYGN, click here.
This article first appeared on GuruFocus.